Navigation Links
Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting
Date:2/27/2012

that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) the outcome of any existing or future intellectual property or other litigation related to our proprietary drug candidates.  Other important risks and uncertainties are detailed in our reports and other filings with the Securities and Exchange Commission ("SEC"), including without limitation, those risks and uncertainties set forth in Nektar's Form 10-Q for the quarter ended September 30, 2011, filed with the SEC on November 4, 2011 and our Form 8-K filed with the SEC on January 11, 2012. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Nektar Investor Inquiries:
Jennifer Ruddock/Nektar Therapeutics                        (415)482-5585
Susan Noonan/SA Noonan Communications, LLC   (212) 966-3650

Nektar Media Inquiries:  
Karen Bergman/BCC Partners                                   (650) 575-1509
Michelle Corral/BCC Partners                                     (415) 794-8662

(1) Lalovic et al., Clinical Pharmacology and Therapeutics, 2006.

(2) 2011 National Academy of Sciences. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research, 2010 Deci
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
2. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
3. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
4. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
7. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
8. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... Fla. and DUBLIN , ... ("we" or the "Company"), a biotechnology company pioneering the ... marketing of innovative therapies for cancer, HIV/AIDS, opportunistic infections ... to its shareholders from CEO Noreen Griffin The letter ... Inc. (the "Company" or "TNIB") received a number of ...
(Date:9/29/2014)... , Sept. 29, 2014  Moberg ( www.moberg.com ... CNS Monitor, a medical device used for advanced ... Mark certifies that a product has met European ... Europe . The CNS Monitor ... (EEG, or brain waves) to support neurological patient ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8Moberg CNS Monitor Receives European CE Mark Approval for Advanced Neurological Monitoring 2
... Annual Meeting- , , ... of a randomized phase III study presented at the ... The study in adult patients with hematological malignancies at ... demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid ...
... Analgesic Significantly Reduces Postop Pain, Opioid Use, and ... Standard Pain Medication , ... A Phase II dose escalation study of a ... who underwent total knee arthroplasty, or TKA, showed ...
Cached Medicine Technology:Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 2Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 3Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 4
(Date:9/30/2014)... Amy Norton HealthDay ... -- Long-acting contraceptive devices should be the first choice ... the American Academy of Pediatrics state. Although most ... two other forms of contraception -- intrauterine devices (IUDs) ... to the academy. And they should be the ...
(Date:9/30/2014)... VA (PRWEB) September 30, 2014 Visit ... of Chestnut Hill and you will find a loving ... together, Amyotrophic Lateral Sclerosis. , Steve was ... or Lou Gehrig’s Disease – just before the couple’s ... primary caregiver. , A new video, “Care, Support ...
(Date:9/30/2014)... Franklin, TN (PRWEB) September 30, 2014 ... millions of people throughout the United States and ... of Parkinson’s Disease are diagnosed each year, adding ... diagnosed with the disease. Approximately 400,000 people in ... 2.3 million worldwide. Add to these statistics the ...
(Date:9/30/2014)... 2014 Pivotal 5, LLC, a proven ... Life Time – The Healthy Way of Life CompanySM ... KettleWorX Group Training . KettleWorX Group Training is a ... offers consumers of all fitness levels a means to ... manner. The rollout to Life Time Athletic destinations will ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 (HealthDay ... the return of a common type of irregular heartbeat known ... percent of those taking fish oil for its omega-3 fatty ... of 16 months, compared to 63.2 percent of those ... the twin ills of inflammation or oxidative stress, which may ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 3Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3
... School of Medicine and colleagues discovered that the Notch ... types, and is also implicated in some cancers, is ... The findings appear this week in Cell Stem Cell, ... bone marrow stem cells. , Notch is one of ...
... the Head and Neck, NEW YORK, April 10 ... plastic and cosmetic surgery for the ethnic,patient, will speak ... day,Continuing Medical Education (CME) Accredited seminar entitled "Patient,Safety in ... 12 at the,University Club of New York., "Facial ...
... Support Event, ALEXANDRIA, Va., April 10 ... (NHDD), will be the largest,effort ever undertaken to ... "With healthcare, ,your decisions matter;, however, others ... Nathan A. Kottkamp, Chair, National,Healthcare Decisions Day. "All ...
... in wine that protect against dementia. This is shown in ... Sweden. , The findings are based on 1,458 women who ... 1968. When they were examined by physicians they were asked ... by selecting from seven categories on a scale from never ...
... - 7,000 deaths a year ... pharmacy error risk, - Half of consumers choose their pharmacies for ... ... One-third of America,s 225,million prescription-takers now report experiencing a prescription ...
... their children to a podiatrist,for foot ailments, BETHESDA, ... bring thousands of adults to doctors, offices every,day. But ... Medical Association (APMA) during April,s Foot Health Awareness,Month, many ... it comes to their children,s feet. In fact, only ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:Dr. Edmund Kwan to Speak on Facial Contouring Among Asian Patients at Cosmetic Surgery Seminar 2Health News:National Healthcare Decisions Day in All 50 States, DC, Puerto Rico, and Internationally 2Health News:Wine may protect against dementia 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Pediatric Survey Reveals Many Parents Neglect Their Children's Feet 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: